Korean Circ J.  2018 May;48(5):433-434. 10.4070/kcj.2018.0081.

Oral Anticoagulants for Atrial Fibrillation Patients with Active Cancer

• Kim DY
• Lim HE

• KMID: 2414913
• DOI: http://doi.org/10.4070/kcj.2018.0081

Abstract

No abstract available.

MeSH Terms

Anticoagulants*
Atrial Fibrillation*
Humans
Anticoagulants

Reference

1. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol. 2014; 63:945–953.

2. Conen D, Wong JA, Sandhu RK, et al. Risk of malignant cancer among women with new-onset atrial fibrillation. JAMA Cardiol. 2016; 1:389–396.

3. Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood. 2013; 122:2310–2317.

4. Lee YJ, Park JK, Uhm JS, et al. Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy. Int J Cardiol. 2016; 203:372–378.

5. Senoo K, Lane D, Lip GY. Stroke and bleeding risk in atrial fibrillation. Korean Circ J. 2014; 44:281–290.

6. Kim K, Lee YJ, Kim TH, et al. Effect of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer. Korean Circ J. 2018; 48:406–417.

7. Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist. 2014; 19:82–93.

8. Hendrie PC, Garcia DA. Are new oral anticoagulants ready for use in patients with cancer? J Natl Compr Canc Netw. 2013; 11:1446–1449.